Dermatology
Latest News
Psychiatric, Autoimmune Comorbidities Increased in Patients with Alopecia Areata
Overall, patients with AA showed a greater prevalence of any psychiatric disease and any immune-mediated or autoimmune disease.
Latest News
Expanded Surface Area Safe, Well-Tolerated for AK treatment
The most common local effects of treatment were erythema and flaking or scaling, with severe cases reported in 5.8% and 8.7% of the patients,...
Latest News
Skin Dxs in Children in Refugee Camps Include Fungal Infections, Leishmaniasis
In a study of 125 children at a Sierra Leone–based displacement camp, the prevalence of scabies was 77% among those aged < 5 years and 86%...
Latest News
Consider Risks, Toxicity of Some Topical Ingredients in Infants, Young Children
The "four Ps" of poisoning -- the physician, pharmacy, parents, and pharmaceutical manufacturing -- all have some responsibility for errors that...
Latest News
Advantages of a Pediatric Rheumatology/Dermatology Clinic Evaluated
The top four primary diagnoses at the clinic were linear morphea (33%), lupus (23%), ...
Latest News
Underserved Families Share Ways to Improve Access to Pediatric Dermatologists
Barriers to receiving pediatric dermatology care included distrust of the healthcare system, distance to the hospital, and household income.
Latest News
Study Finds Gout Drug Effective for Aphthous Ulcers in Children
“Complex aphthous stomatitis in children is typically treated with topical supportive care, which is often not effective,” one of the study...
Latest News
FDA Approves Deuruxolitinib for Severe Alopecia Areata in Adults
Deuruxolitinib, which comes in 8-mg tablets, is an oral selective inhibitor of JAK1 and JAK2 and is administered twice a day.
Latest News
Pilot Study Finds Experimental CBD Cream Decreases UVA Skin Damage
Histology showed that CBD-treated skin demonstrated reduced UVA-induced epidermal hyperplasia compared with control-treated skin.
Latest News
Study Finds Differences in Side Effect Profiles With Two Oral Psoriasis Therapies
The results were based on data from the FDA’s Adverse Event Reporting System.
Latest News
Risk of MACE Comparable Among Biologic Classes for Psoriasis, PsA
Despite some concern about increased risk for MACE with TNFi use, this study suggests no special risk for patients with psoriasis or PsA...